Patents Assigned to The Center for Blood Research, Inc.
-
Patent number: 8241627Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: GrantFiled: June 22, 2011Date of Patent: August 14, 2012Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Publication number: 20110305691Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: ApplicationFiled: June 22, 2011Publication date: December 15, 2011Applicant: THE CENTER FOR BLOOD RESEARCH, INC.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 7968284Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: GrantFiled: December 10, 2010Date of Patent: June 28, 2011Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Publication number: 20110111528Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: ApplicationFiled: December 10, 2010Publication date: May 12, 2011Applicant: THE CENTER FOR BLOOD RESEARCH, INC.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 7879577Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: GrantFiled: November 20, 2009Date of Patent: February 1, 2011Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Publication number: 20100113742Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: ApplicationFiled: November 20, 2009Publication date: May 6, 2010Applicant: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 7674604Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. Modified integrin I-domain polypeptides stabilized in a desired conformation are also provided, as well as screening assays and therapeutic methods utilizing the modified integrin I-domain polypeptides.Type: GrantFiled: March 15, 2005Date of Patent: March 9, 2010Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 7569229Abstract: The invention relates to an anti-inflammatory oligopeptide which can be obtained from the microorganism Entamoeba histolytica or synthesized by known methods. The oligopeptides are useful in treating inflammatory diseases when formulated in pharmaceutical compositions for administration to patients.Type: GrantFiled: February 29, 2008Date of Patent: August 4, 2009Assignee: Center for Blood Research, Inc.Inventor: Roberto Rodolfo Kretschmer Schmid
-
Publication number: 20080167253Abstract: The invention relates to an anti-inflammatroy oligopeptide which can be obtained from the microorganism Entamoeba histolytica or synthesized by known methods. The oligopeptides are useful in treating inflammatory diseases when formulated in pharmaceutical compositions for administration to patients.Type: ApplicationFiled: February 29, 2008Publication date: July 10, 2008Applicant: Center for Blood Research, IncInventor: Roberto Rodolfo Kretschmer Schmid
-
Patent number: 7387777Abstract: The present invention identifies P-selectin as a modulator of hemostasis. Accordingly, the present invention relates to methods for the identification and use of modulators of P-selectin activity as modulators of hemostasis. The invention also relates to methods and compositions for the diagnosis and treatment of hemostatic disorders, including, but not limited to, hemorrhagic disorders and thrombotic disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hemostatic conditions, and for the identification of subjects exhibiting a predisposition to such conditions. In addition, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of a hemostatic or vascular disorders, and for monitoring the efficacy of compounds in clinical trials.Type: GrantFiled: February 19, 2004Date of Patent: June 17, 2008Assignee: Center For Blood Research, Inc.Inventors: Denisa D. Wagner, Patrick Andre, Daqing W. Hartwell, Ingrid Hrachovinova
-
Patent number: 7241869Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.Type: GrantFiled: March 15, 2005Date of Patent: July 10, 2007Assignee: Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 7160541Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. Modified integrin I-domain polypeptides that are stabilized in a desired conformation are also provided. Finally, screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention are also provided.Type: GrantFiled: August 31, 2001Date of Patent: January 9, 2007Assignee: The Center for Blood Research, Inc.Inventors: Timothy A. Springer, Motomu Shimaoka, Chafen Lu
-
Patent number: 6797270Abstract: The invention concerns the use of functional derivatives of ICAM-1 to treat viral infection. The invention also provides a vaccine to prevent such infection, and a diagnostic assay to determine the existence and extent of such infection.Type: GrantFiled: April 11, 1995Date of Patent: September 28, 2004Assignee: Center for Blood Research, Inc.Inventors: Timothy A. Springer, Donald E. Staunton
-
Publication number: 20040171073Abstract: Methods for regulation of lipid and cholesterol uptake are described which are based on regulation of the expression or function of the SR-BI HDL receptor. The examples demonstrate that estrogen dramatically downregulates SR-BI under conditions of tremendous upregulation of the LDL-receptor. The examples also demonstrate the upregulation of SR-BI in rat adrenal membranes and other non-placental steroidogenic tissues from animals treated with estrogen, but not in other non-placental non-steroidogenic tissues, including lung, liver, and skin. Examples further demonstrate the uptake of fluorescently labeled HDL into the liver cells of animal, which does not occur when the animals are treated with estrogen. Examples also demonstrate the in vivo effects of SR-BI expression on HDL metabolism, in mice transiently overexpressing hepatic SR-BI following recombinant adenovirus infection. Overexpression of the SR-BI in the hepatic tissue caused a dramatic decrease in cholesterol blood levels.Type: ApplicationFiled: October 8, 2003Publication date: September 2, 2004Applicants: Massachusetts Institute of Technology, Center for Blood Research, Inc.Inventors: Thomas J.F. Neiland, Monty Krieger, Tomas Kirchausen
-
Patent number: 6777191Abstract: The invention concerns the use of functional derivatives of ICAM-1 to treat viral infection. The invention also provides a vaccine to prevent such infection, and a diagnostic assay to determine the existence and extent of such infection.Type: GrantFiled: June 7, 1995Date of Patent: August 17, 2004Assignee: Center for Blood Research, Inc.Inventors: Timothy A. Springer, Donald E. Staunton
-
Publication number: 20030064380Abstract: Methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of an immune disorder. In particular, the present invention is directed to the identification of novel targets which are anergy markers. The present invention is further directed to methods of high-throughput screening for test compounds capable of modulating the activity of proteins encoded by the novel targets. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit an immune disorder. Methods for determining the long term prognosis in a subject are also provided.Type: ApplicationFiled: January 29, 2002Publication date: April 3, 2003Applicant: The Center For Blood Research, Inc.Inventors: Anjana Rao, Michael Byrne, Fernando Macian
-
Patent number: 6436403Abstract: The invention concerns the use of functional derivatives of ICAM-1 to treat viral infection. The invention also provides a vaccine to prevent such infection, and a diagnostic assay to determine the existence and extent of such infection.Type: GrantFiled: June 7, 1995Date of Patent: August 20, 2002Assignee: Center for Blood Research, Inc.Inventors: Timothy A. Springer, Donald E. Staunton
-
Publication number: 20010023072Abstract: A method for the enrichment of dendritic cells from the peripheral blood of a mammal is described. Peripheral blood having mononuclear cells from a mammal is provided. The mononuclear cells are separated from the peripheral blood. The mononuclear cells are separated into a first cell population having substantially lymphocytes and a second cell population having substantially myeloid cells. The myeloid cells are separated into a third cell population having substantially monocytes and a fourth cell population having substantially dendritic cells. Also described are purified dendritic cell populations, vaccine compositions and methods for the treatment of cancer using dendritic cells, and kits useful for the enrichment of dendritic cells from blood.Type: ApplicationFiled: January 31, 2001Publication date: September 20, 2001Applicant: The Center For Blood Research, Inc.Inventors: Keith D. Crawford, Chester A. Alper
-
Patent number: 6274342Abstract: The present invention relates to the discovery of novel genes encoding Monocyte Chemotactic Protein-5 (MCP-5) polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.Type: GrantFiled: November 8, 1996Date of Patent: August 14, 2001Assignee: Center for Blood Research, Inc.Inventors: Jose-Carlos Gutierrez-Ramos, Gui-Quan Jia, Jose-Angel Gonzalo
-
Patent number: 6197531Abstract: A method for determining the immunocompetence of a mammal is described. Bodily fluid having T cell receptor complexes from a mammal is provided. Expression of a first component and a second component of the T cell receptor complexes is evaluated. An abnormal ratio of the number of cells expressing the first component as compared to the number of cells expressing the second component indicates altered immunocompetence in the mammal.Type: GrantFiled: January 21, 1998Date of Patent: March 6, 2001Assignee: Center For Blood Research, Inc.Inventor: Judy Lieberman